MicroRNA profiling in human breast cancer cell lines exposed to the anti-neoplastic drug cediranib by Bordinhão, A. L. R. et al.
ONCOLOGY REPORTS  36:  3197-3206,  2016
Abstract. Cediranib, a pan-tyrosine kinase inhibitor is 
showing promising results for the treatment of several solid 
tumours. In breast cancer, its effects remain unclear, and 
there are no predictive biomarkers. Several studies have 
examined the expression profiles of microRNAs (miRNAs) 
in response to different chemotherapy treatments and found 
that the expression patterns may be associated with the treat-
ment response. Therefore, our aim was to evaluate the cellular 
behaviour and differential expression profiles of miRNAs in 
breast cancer cell lines exposed to cediranib. The biological 
effect of this drug was measured by viability, migration, inva-
sion and cell death in in vitro assays. Signaling pathways were 
assessed using a human phospho-receptor tyrosine kinase 
array. Furthermore, using a miRNA array and quantitative 
real-time PCR (qRT-PCR), we assessed the relative expression 
of miRNAs following cediranib treatment. The breast cancer 
cell lines exhibited a distinct cytotoxic response to cediranib 
treatment. Cediranib exposure resulted in a decrease in the 
cell migration and invasion of all the breast cancer cell lines. 
Treatment with cediranib appeared to be able to modulate the 
activation of several RTKs that are targets of cediranib such 
as EGFR and a new potential target ROR2. Furthermore, this 
drug was able to modulate the expression profile of different 
microRNAs such as miR-494, miR-923, miR-449a, miR-449b 
and miR-886-3 in breast cancer cell lines. These miRNAs are 
reported to regulate genes involved in important molecular 
processes, according to bioinformatics prediction tools.
Introduction
Breast cancer is the second most prevalent neoplastic disease 
among women and is characterised by a complex aetiology 
and chemoresistant behaviour (1,2). Although most women are 
treated with tamoxifen, the current standard adjuvant therapy 
in women with estrogen receptor (ER)-positive breast cancer, 
they develop resistance to the drug (3). Cediranib (AZD2171, 
Recentin, AstraZeneca) is a potent inhibitor of several 
receptor tyrosine kinases (RTKs), such as VEGFR, KIT and 
PDGFRA (4,5). Significant results have been obtained for 
patients with advanced solid tumours, such as glioblastoma, 
lung and prostate tumours, after cediranib treatment (6-9). 
Recently, novel targets of cediranib have been identified by 
in vitro and in vivo studies with glioblastoma cell lines (10). 
Furthermore, it was shown that cediranib alone or in combina-
tion with temozolomide is an effective drug in anti-angiogenic 
therapies due to its greater antitumour activity (10). Animal 
models of breast cancer revealed that cediranib affected 
vessel density and cell proliferation, but not with chronic 
administration (11,12). Phase I/II studies have been conducted 
with cediranib for breast cancer treatment, especially in 
combination with other drugs, such as fulvestrant, olaparib 
and RO4929097, a γ-secretase inhibitor (13-15). The promise 
of cediranib treatment is an improvement in overall survival 
of up to six months in several tumour types (6,7), and while 
it has not yet been approved by the FDA, cediranib, alone or 
in combination with other drugs, represents a new potential 
therapy for breast cancer.
Despite these observations, in breast cancer cell lines, the 
effects of cediranib on cellular processes such as proliferation, 
migration and invasion are unknown. Therefore, exploring the 
biological effect of cediranib on breast cancer cell lines and 
revealing the pathways that can be predictive biomarkers of 
cediranib response are necessary. MicroRNAs (miRNAs) are 
small noncoding RNAs approximately 22-26 nucleotides (nt) 
long that are involved in post-transcriptional repression or 
mRNA degradation in a sequence-specific manner (16,17). The 
role of miRNAs as new regulatory molecules that are involved 
in different cancer processes have recently emerged (18). 
Several studies on miRNA profiling have shown that these 
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molecules can act as oncogenes and tumour suppressors (19). 
Accordingly, strategies to correct the deficiencies associated 
with miRNA dysregulation have been proposed as future 
clinical interventions for cancer patients (20). In breast 
cancer, several miRNAs have been described in several 
steps of tumorigenesis, angiogenesis and metastasis (21-23). 
Furthermore, miRNAs have been considered as potential 
biomarkers in breast cancer metastasis (24).
miRNAs also play a role in anticancer drug resistance (25). 
Several miRNAs have been associated with chemoresistance 
in breast cancer, including miR-34a with docetaxel, miR-125b 
with anthracycline, miR-451 and miR-27 with doxorubicin 
and miR-326 with doxorubicin and VP-16 resistance (26-31). 
Several reports have shown that deletions of miRNA regions 
can affect the regulation of RTKs and the response to gefitinib 
or imatinib (32,33), reinforcing a possible role for miRNAs 
in the mechanism of the response and/or resistance to RTK 
inhibitors.
Overall, miRNAs can affect breast cancer drug sensitivity 
with implications in clinical management and in understanding 
the molecular mechanisms that may contribute to drug suscep-
tibility and resistance (17). Therefore, in the present study, we 
aimed to evaluate the miRNA expression profiles of breast 
cancer cell lines exposed to cediranib.
Materials and methods
Cell lines and determination of the half-maximal inhibi-
tory concentration (IC50). In the present study, the breast 
carcinoma cell lines hs578T, MDA-Mb-231 and T47D were 
obtained from the American Type Culture Collection (ATCC; 
Manassas, VA, uSA). Cells were cultured in Dulbecco's modi-
fied Eagle's medium (DMEM 1X, high glucose), supplemented 
with 10% FbS (both from Gibco, Invitrogen Life Technologies 
Grand Island, NY, uSA) and 1% penicillin and streptomycin 
solution (Sigma-Aldrich) at 37˚C and 5% CO2.
Authentication of cell lines was performed by short tandem 
repeat (STR) DNA typing according to the International 
Reference Standard for Authentication of human Cell Lines 
using a panel of eight (D5S818, D13S317, D7S820, D16S539, 
vWA, Th01, TPOX and CSF1P0) STR loci plus gender deter-
mination (AMEL), using the fluorescent labeling primers as 
reported by Dirks et al (34). briefly, 50 ng of DNA was ampli-
fied in multiplex PCR reaction carried out in a total volume 
of 10 µl with qiagen Multiplex PCR kit (qiagen) comprising 
0.5 µM of all fluorescent primer pairs plus 1 µM of Th01 
primer reinforcement, performed in a Veriti® 96-well Thermal 
Cycler with an initial denaturation at 95˚C for 15 min, ampli-
fied for 30 cycles of denaturation at 95˚C for 30 sec, annealing 
at 55˚C for 1 min 30 sec, extension at 72˚C for 1 sec and a 
final cycle at 72˚C for 30 min. The DNA amplification products 
were diluted 1:100 in Nuclease-Free Water ultrapure (uSb, 
Cleveland, Oh, uSA) and combined with 0.3 µl of internal size 
standard GeneScan 500™ ROX™ (Applied biosystems, Foster 
City, CA, uSA) in 8.7 µl formamide and loaded automati-
cally in a capillary electrophoresis using an Genetic Analyzer 
AbI PRISM 3500 (Applied biosystems). The analysis was 
performed in GeneMapper software version 4.1 (Applied 
biosystems). Genotyping confirmed the identity of all three 
cell lines.
The drug used, cediranib (Selleck Chemicals, houston, TX, 
uSA), was diluted in 1% DMSO. To determine the IC50, the 
cells were plated in increasing concentrations of the drug from 
0.1 to 100 µM, and an MTS proliferation assay was performed. 
The IC50 concentration was calculated using the drc package in 
R (35,36), and the best model for each cell type was selected 
according to the Akaike information Criterion (AIC).
Invasion and migration assays. The invasion assays were 
performed using bD bioCoat Matrigel invasion chambers 
(bD biosciences) according to the manufacturer's instructions 
and as previously described (10,37). briefly, 2.5x104 cells 
were plated in the Matrigel-coated 24-well Transwell inserts 
in DMEM-0.5% containing fixed concentrations of the drug. 
DMEM-10% was used as a chemoattractant, and the cells 
that attached to the inserts were fixed with methanol and 
stained with haematoxylin. The cells were photographed at a 
x40 magnification level and counted on a pixel-by-pixel basis 
using ImageJ software. The invasiveness of the cells exposed 
to cediranib (IC50 dose at 72 h) was expressed in relation to 
the DMSO control (considered 100% invasion) as the mean 
percentage of invasion ± SD. The assays were performed in 
triplicate.
The migration capacity of the cells after cediranib expo-
sure was assessed using a wound-healing assay as previously 
described (10,38). The cells were seeded in 6-well plates and 
cultured until reaching 95% confluency. The monolayer of cells 
was washed with PbS; a wound was created, and the cells were 
incubated with the IC50 concentrations of cediranib for varying 
times. The selected areas were photographed at x40 magnifi-
cation at 0 to 24 h for the hs578T and MDA-Mb-231 cells and 
at 0 to 72 h for T47D cells. The relative migration distance was 
calculated using the following formula: Percentage of wound 
closure (%) = 100(A − b)/A, where A is the width of the cell 
wound before incubation and B is the width of the cell wound 
after different lengths of cediranib exposure. The assay was 
performed in triplicate with four measurements for each well.
Western blot analysis and human phospho-RTK array. To 
evaluate the inhibition of the intracellular signalling pathways, 
hs578T, MDA-Mb-231 and T47D cells were cultured in T25 
culture flasks in DMEM 10% FbS. After reaching 90% conflu-
ency, the cell lines were starved and exposed to cediranib 
(IC50 values) for 12 h. Analysis of apoptosis was conducted in 
6-well culture plates at 70% confluency and incubated for 12, 24 
and 72 h. For all experiments, after time points, the cell lines were 
washed and scraped in cold PBS and lysed in buffer, containing 
50 mM Tris, 150 mM NaCl, 5 mM EDTA, 1 mM Na3VO4, 10 mM 
NaF, 10 mM sodium pyrophosphate, 1% NP-40 and protease 
cocktail inhibitors. Western blot analysis was performed using 
standard 10% sodium dodecyl sulphate polyacrylamide gel elec-
trophoresis (SDS-PAGE) loading 30 µg protein per line. To assess 
apoptosis and the activation of intracellular signaling pathways, 
the antibodies used were the following: primary antibody PARP 
total/cleaved [Cell Signaling Technology (CST), no. 9532]; total 
p44/42 MAPK (CST, no. 137F5) and phospho-p44/42 MAPK 
(CST, no. 8544); pan AKT (CST, no. C67E7) and phospho-Akt 
(Ser473) (CST, no. 4060); β-actin (CST, no. 12262). Secondary 
antibodies were used according to the manufacturer's instruc-
tions. Immune blots were performed using ECL western 
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blotting detection reagent (GE healthcare) and finally the bands 
were detected and images were captured using an Automatic 
Imagequant Mini LAS 4000 (GE healthcare).
human phospho-RTK array (PN no. 894042, R&D 
Systems) was used according to the manufacturer's instruc-
tions. In brief, after the blocking step, 750 µg of protein were 
incubated overnight at 4˚C with nitrocellulose membranes 
containing 49 different anti-RTK Abs spots in duplicate. Next 
they were incubated with anti-phospho-tyrosine-hRP for 2 h 
and detection was performed with a Chemi Reagent Mix in 
Automatic Imagequant Mini LAS 4000 (GE healthcare).
RNA isolation and quality control. Total RNA was isolated 
using an miRNeasy kit (qiagen) according to the manufac-
turer's instructions. quantification was performed using 
a NanoDrop ND-1000 spectrophotometer (NanoDrop 
Products, Wilmington, DE, uSA), and the RNA quality was 
assessed using an Agilent Nano RNA chip with a bioanalyser 
device (Agilent Technologies), as previously described (39).
miRNA microarrays. To assess the expression of miRNAs 
after 24 h of treatment with an IC50 dose of cediranib in 
hs578T, MDA-Mb-231 and T47D cells and the same cell 
lines without treatment were considered as controls, the 
Agilent human miRNA Microarray (8x15K-G4471A, Agilent 
Technologies) was used. Total RNA samples (200 ng) were 
hybridised using an miRNA complete labelling and a hyb 
kit (Agilent Technologies) according to the manufacturer's 
instructions. The reactions followed a two-step preparation; 
an initial dephosphorylation and denaturation of the total 
RNA was performed, and the Cy3 fluorochrome was then 
incorporated with T4 ligase. The next steps included standard 
washing procedures and hybridisation with the microarray 
slides. Images were scanned with an Agilent DNA microarray 
scanner with SureScan technology (Agilent Technologies), as 
previously described (40).
miRNA microarray data analysis. The raw data were 
obtained using the Feature Extraction software v.11.0 (Agilent 
Technologies) and submitted to R environment version 3.0.1 (36) 
for additional analyses. Median signals (gMedianSignal 
and gBGMedianSignal) were used as intensity values. 
Normalisation was performed using the quantile method 
with the bioconductor ‘aroma.light’ package (41). miRNAs 
differentially expressed between the cediranib-treated and 
control cells were obtained by rank product analysis consid-
ering a P-value and pfp (positive false predictions) ≤0.05 using 
the RankProd package (42). heatmaps of the differentially 
expressed miRNAs were constructed using hclust R and the 
distance and average Pearson linkage were determined using 
the gplots R package (43).
Target prediction and functional analysis. Target prediction 
was performed using the mirDIP interface (44). At least 3 of 
the 12 available algorithms were selected for prediction. To 
perform a functional enrichment analysis, all the targets were 
separated according to up- or downregulation and submitted 
to the Database for Annotation, Visualization, and Integrated 
Discovery (DAVID) (45). This approach was used to identify 
significant biological processes in Gene Ontology level 2 that 
may be shared among the targets of the miRNAs of interest. 
A biological process or pathway was considered significant 
if it contained a minimum of 3 genes per category that had 
score values <0.05 after a benjamini-hochberg correction. A 
compilation of the categories according to a GoSlim summari-
sation was performed using the REVIGO tool (46).
Confirmation by quantitative real-time PCR (qRT-PCR). 
qRT-PCR using TaqMan miRNA assays (Life Technologies, 
Foster City, CA, uSA) was used to confirm the expres-
sion of five miRNAs from the microarray data that were 
differentially expressed between cells exposed to cediranib 
compared with the control group. The criterion for selecting 
the miRNAs for confirmation was the level of expression. 
All of the samples used in the microarray experiments were 
performed in technical triplicates for the RT-PCR reactions. 
A total of 10 ng of RNA was used in the reverse transcrip-
tion reaction with miRNA-specific primers in an Eppendorf 
Mastercycler (Eppendorf). The real-time reactions were 
performed in a 7900 hT Fast Real-time PCR system (Applied 
biosystems).
All of the analysis procedures and graphs were constructed 
using the R environment v.3.0.1. The normalisation step 
was performed according to the 2-ΔΔCt method (47) using 
the minimum value of expression of the untreated group 
as a calibrator. The cycle threshold (Ct) values from the 
selected miRNA targets were subtracted from the Ct values 
of the endogenous small noncoding RNA controls RNu44 
Table I. half-maximal inhibitory concentration (IC50) at 24, 48 
and 72 h of cediranib exposure in the hs578T, MDA-Mb-231 
and T47D cells.
 IC50 (µM) ----------------------------------------------------------------------------------
Cell line 24 h 48 h 72 h
hs578T 10.66±0.66 2.51±0.62 2.08±0.77
MDA-Mb-231 30.77±2.01 15.57±3.03 2.52±0.81
T47D 38.69±2.90 26.54±2.79 18.85±3.21
Figure 1. half-maximal inhibitory concentration (IC50) in log2 scale in µM 
at 24, 48 and 72 h of cediranib exposure in the hs578T, MDA-Mb-231 and 
T47D cells.
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and RNu48 (control miRNA assay; Applied biosystems). 
The criterion for selecting the best endogenous RNA was 
the stability of expression according to the NormFinder 
software (48). Differences in miRNA expression between the 
treated and non-treated cell lines (hs578T, MDA-Mb-231 
and T47D) were evaluated using Mann-Whitney u test, and 
differences with a P≤0.05 were considered significant.
Results
Following an initial assessment of the basal viability condi-
tions for all the three breast cell lines, a total density of 
4x103 cells/well for hs578T, 6x103 cells/well for MDA-Mb-231 
and 1x104 cells/well for the T47D cell line was used. The IC50 
was then determined for the breast cancer cells at 24, 48 and 
72 h, as shown in Table I and Fig. 1. Our results showed that 
the most sensitive breast cancer cell line was hs578T, followed 
by MDA-Mb-231. The T47D cell line was the most resistant, 
with an IC50 value 4-fold higher than that of the hs578T cells 
and almost 2-fold higher than that of the MDA-Mb-231 cells 
after a 24-h treatment.
To determine whether decreased viability was due to 
cytotoxic effects, we analyzed poly(ADP ribose) poly-
merase (PARP) cleavage. We observed a striking effect on 
PARP cleavage using low doses (0.5 and 2.0 µM) of cediranib 
in the hs578T cell line. Similar effects were demonstrated 
in the MDA-Mb-231 cell line that exhibited higher cleaved 
PARP levels. In contrast, the T47D cell line showed lower 
PARP cleaved levels (8 and 18 µM) using a high dose of cedi-
ranib drug, representing a resistant profile. Cytotoxic effects 
demonstrated by cleaved PARP were not found at times less 
than 24 h for both cell lines (Fig. 2).
In order to assess the functional impact of cediranib in 
migration, we used the wound-healing migration assay, and 
observed the inhibition of cell migration in all of the cell 
lines. After 24 h of cediranib exposure, the hs578T cells 
exhibited the most inhibition (80%), followed by the T47D 
cells (70%) and MDA-Mb-231 cells (54%) (Fig. 3). Even the 
adhesion of this cell type appeared to be affected by the drug 
(data not shown), leading to negative values, i.e., the wound 
was extended because of the detachment of these cells. Due 
to this behaviour, we studied the T47D migration ability for 
72 h. Similarly, cediranib treatment significantly inhibited cell 
invasion in all breast cancer cell lines. The reduction in the 
percentage of cell invasion at 24 h was ~70% in T47D, 60% in 
hs578T and 30% in the MDA-Mb-231 cells (Fig. 4).
Figure 2. Apoptosis was evaluated by western blot analysis for poly(ADP ribose) polymerase (PARP) cleavage. breast cancer cell lines were exposed to 
cediranib (IC50 values) at 12, 24 and 48 h.
Figure 3. Effect of cediranib on cell migration in the (A) hs578T cells evaluated from 6 to 24 h, (b) MDA-Mb-231 cells from 6 to 24 h and (C) T47D cells from 
12 to 72 h. The relative distance of migration was measured with a wound-healing migration assay. The data are represented as the means ± SD, and differences 
with *P<0.05 according to Student's t-test were considered statistically significant.
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To identify the RTKs that are targets of cediranib, we used 
a phospho-RTK array that assesses the levels of 49 RTKs, in 
the most sensitive cell line, hs578T, which was exposed to 
2 µM cediranib. under basal levels, we observed the presence 
of the active forms of EGFR, Tie-2, RYK, FGFR2α, m-CSFR, 
c-RET, AXL and ROR2 (RTK-like orphan receptor 2) tyrosine 
kinase receptors (Fig. 5A). Following cediranib treatment, we 
found a slight increase in EGFR and Tie-2 phosphorylation 
levels (Fig. 5A-C) and diminished phosphorylation levels of 
FGFR2α and ROR2. We did not detect any significant changes 
in the phosphorylation of the other RTKs after treatment with 
cediranib (Fig. 5C).
We further addressed the inhibitory effect of cediranib in 
intracellular pathways, using higher concentrations of the drug 
for 12 h in both cell lines (Fig. 5D). We observed a decrease 
in ERK phosphorylation at the concentrations analyzed in 
the hs578T cells. however, this cell line showed that the 
inhibition of AKT seemed to be dose-dependent (2 µM) after 
cediranib treatment. both cell lines, hS578T and MDA-Mb-
231, were exposed to equal cediranib concentrations (0.5 and 
2 µM), and only the MDA-Mb-231 cell line did not exhibit 
decreased ERK phosphorylation levels. The absence of AKT 
phosphorylation was detected in the MDA-Mb-231 cell line. 
The phosphorylation levels of ERK and AKT were unchanged 
in the T47D cell line after exposure to cediranib (Fig. 5D).
To further identify potential miRNAs in response to 
cediranib, we performed miRNA expression profiles in each 
Figure 4. Invasion was assessed using a Matrigel invasion assay in the 
hs578T, MDA-Mb-231 and T47D cells. The invasion of cells exposed 
to cediranib (IC50 at 72 h) was expressed in relation to the DMSO control 
(100%). The additional dose (dose 2) represents the average of the IC50 doses 
at 24 and 72 h. The data are represented as the means ± SD, and differences 
with *P<0.05 according to the Student's t-test were considered statistically 
significant.
Figure 5. Effects of cediranib on activation of the intracellular pathway and receptor tyrosine kinases (RTKs) in the hs578T cell line. (A) Profile of the human 
phospho-RTK array of untreated hs5678T cell line. (b) Profile of the human phospho-RTK array of the hs578T cell line treated with 2 µM of cediranib for 
4 h. (C) Densitometric analysis of proteins (spots). (D) Activation of the intracellular pathways ERK and AKT. All cell lines were incubated with increasing 
concentrations of cediranib for 2 h and the phosphorylation levels were detected by western blot analysis.
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Figure 6. heatmaps of all of the differentially expressed miRNAs compared with the controls after 24 h of cediranib exposure in the (A) hs578T, 
(b) MDA-Mb-231 and (C) T47D cells.
Figure 7. Summary of significant functional categories (Gene Ontology level 2) among the targets of differentially expressed miRNAs in (A) hs578T, 
(b) MDA-Mb-231 and (C) T47D cells. P-values are represented using a -log10 scale.
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breast cancer cell line and compared them with the controls. 
The results revealed 31 differentially expressed miRNAs in 
the hs578T cells, 13 miRNAs in the MDA-Mb-231 cells 
and 7 miRNAs in the T74D cell line (Fig. 6). The targets of 
these identified miRNAs are summarised according to their 
biological processes. The hs578T cell line shared several 
processes with the MDA-Mb-231 cells, including the induction 
of a response to endogenous/chemical stimuli, biosynthesis, 
vesicle-mediated transport, the movement of cellular compo-
nents, the repression of the ubiquitin cycle, and the regulation 
of anti-apoptosis and cell death (Fig. 7). The T74D cell line 
presented specific biological processes; only biosynthesis was 
upregulated in the other cell lines in a similar manner, while 
vesicle-mediated transport and cellular component movement 
were repressed (Fig. 7).
Among the miRNAs identified, five miRNAs, miR-494, 
miR-923, miR-449a, miR-449b and miR-886-3p, were 
selected for further confirmation of expression due to the 
greater change in expression and the biological relevance of 
these miRNAs (Fig. 8). The endogenous miRNA RNu-48 was 
the most stable in our results, and this miRNA was thus used 
for all the analyses. The results confirmed the overexpression 
of miR-494 and miR-923 in the hs578T cells exposed to cedi-
ranib compared to the control cells. In the MDA-Mb-231 cells, 
the overexpression of miR-923 and the decreased expression 
of miR-886-3p after exposure to cediranib were confirmed. 
both miR-449a and miR-449b were dowregulated in the T47D 
cell line after cediranib treatment.
Discussion
Cediranib is a tyrosine kinase inhibitor that represents promise 
in the treatment of several tumours (6). The main targets of 
this pharmacological drug are the VEGFR proteins, which 
regulate blood vessel formation in tumours and are associated 
with the anti-angiogenic effects of cediranib (4). In the present 
study, we showed that cediranib exhibited an effect on breast 
cancer cells, affecting cell migration and invasion, and the 
molecular processes associated with the miRNA expression 
altered in response to treatment was also studied.
Regarding the sensitivity to the agent, the IC50 value varied 
according to the cell line used. The most sensitive cell line 
(hs578T) had IC50 values (~2 µM) similar to those of glioma 
cells after 72 h of cediranib exposure (10). Notably, PARP is 
an abundant, chromatin-associated enzyme which responds to 
DNA damage (49). Our results showed that when exposed to 
cediranib (according to the IC50 values) the cell line hs578T 
displayed cleavage of PARP at 48 h of exposure, followed by 
MDA-Mb-231 and T47D cell lines. based on this result, we 
demonstrated that the hs578T cell line had greater sensitivity 
to cediranib. ERK inhibition was detected only in sensitive cell 
line hs578T, showing the efficient inhibition in the conserved 
RAS-mitogen activated protein kinase (MAPK) signalling 
pathway which may affect the cellular growth, survival, and 
differentiation (50). In the MDA-Mb-231 and T47D cell lines, 
the phosphorylation of ERK was not significantly blocked. A 
recent study showed similar results in another breast cancer 
Figure 8. qRT-PCR confirmation of the miRNAs that were differentially expressed according to the microarray analysis in the (A) hs578T, (b) MDA-Mb-
231 and (C) T47D cells. The data are represented as the means ± SD, and differences with *P<0.05 according to Student's t-test were considered statistically 
significant.
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cell line, which presented a resistance profile when exposed 
to cediranib at 1-10 µM/l (51). The persistent AKT activation 
in some solid cancers, such as non-small cell lung carci-
nomas (NSCLCs), is associated with TKI response (52). We 
observed a total blockade of the AKT phosphorylation in the 
hs578T cell line when exposed to different cediranib concen-
trations. however the MDA-Mb-231 cell line showed absence 
of phosphorylated proteins and T47D displayed no significant 
changes. Therefore, we may hypothesized that AKT inhibition 
may be related with cediranib response in breast cancer cell 
lines.
The proteome profiler of phospho-RTKs showed that 
although hs578T cells did not express the described cediranib 
targets under baseline conditions, such as VGFRs, KIT or 
PDGFRA, this cell line exhibited other important RTKs, such 
as EGFR, Tie-2, RYK, FGFR2α, m-CSFR, c-RET, AXL and 
ROR2, and upon cediranib exposure we observed reduction of 
the ROR2 and FGFR2α RTKs. ROR2 is a novel Wnt receptor 
recently discovered and is associated with progression of 
solid tumours such as melanoma, osteosarcoma and prostate 
cancer (53). An immunohistochemistry study conducted in 
patients with breast cancer showed ROR2 overexpression in 
87% of the cases, and its association with a worse outcome (54). 
Further studies are needed to validate our findings, and more 
importantly to determine whether the expression levels of 
ROR2 and FGFR2α in human breast cancer tissue may predict 
the response to cediranib.
Regarding the expression of miRNAs, the hs578T cell 
line presented a greater number of modulated miRNAs 
than the MDA-Mb-231 and T47D cell lines, as an indicator 
of sensitivity to the drug. Although the hs578T cell line 
presented 22 specific miRNAs, the most significant biological 
processes, such as biological regulation, development, meta-
bolic processes, cell motility and homeostasis, were related 
to targets that were shared with the MDA-Mb-231 cell line, 
including VEGFA, VEGFC, and PDGFRA. Several studies 
support the roles of these molecules in these processes, espe-
cially roles in tissue metabolism and homeostasis in breast 
cancer (55,56).
Of the targets shared between the hs578T and 
MDA-Mb-231 cell lines, miR-923 upregulation was observed. 
Moreover, few miRNAs were upregulated in our findings. 
miR-923 dysregulation was highly associated with drug resis-
tance. The upregulation of this miRNA was also observed in 
breast cancer cells that are resistant to Taxol (57). In the same 
study, miR-125b was upregulated, which was associated with 
bcl-2 antagonist killer 1 (bak1) expression. In our findings, 
miR-125b was also modulated but was downregulated. The 
interaction between specific targets may further be explored. 
miR-923 and miR-886-3p, which were also validated in the 
present study, were shown to be involved in cisplatin resis-
tance in bladder cancer; changes in expression were also 
correlated with survival (58). The upregulation of miR-923 
was also associated with multidrug resistance in the hEp-2 
cell line (59).
Among the specific miRNAs found in the MDA-Mb-231 
cell line, miR-886 has been recently proposed as a vault 
RNA (vtRNA2-1), which may form a complex that is implicated 
in cancer drug resistance. Recently, Lee et al (60) identified 
pre-miR-886 as a 102-nt, abundant cytoplasmic RNA that 
is neither a pre-miRNA nor a vault RNA but is a noncoding 
molecule (nc886). Some evidence indicates that nc886 in an 
immature state is physically associated with PKR (protein 
kinase RNA-activated), a double-stranded RNA-dependent 
kinase (61).
The involvement of miR-886 in the drug response and the 
modulation of this molecule by cediranib in the sensitive cell 
line MDA-Mb-231 supports evidence that some mechanisms 
related to apoptosis could be activated in this context and affect 
the sensitivity of these cells, as observed in the present study. 
In addition, miR-886-3p repression was recently described as 
being mediated by methylation processes in lung cancer cell 
lines (62) and can affect cell proliferation, migration, and 
invasion in lung and non-medullary thyroid cancer (63,64). 
This fact is in concordance with our findings because we 
determined that migration and invasion processes were highly 
affected by cediranib in MDA-Mb-231 cells.
In contrast to the other cell lines studied, few miRNAs were 
modulated in the T47D cell line. The T47D-specific miRNAs 
miR-449a and miR-449b were highly downregulated, and these 
results were confirmed via qRT-PCR. The miRNA miR-449 
has been identified in a wide range of tumours (65-69) and has 
several identified targets, including c-Myc and c-Met (66,67). 
This miRNA induces cell cycle progression and apoptosis by 
regulating CDK6 and CDC25A, direct targets that lead to the 
phosphorylation of E2F1 (70-72). In contrast to the hs578T 
and MDA-Mb-231 cells, no target associated with VEGFR 
or PDGFRA was identified in the T47D cells with the target 
prediction. Considering the difference in the T47D resistance 
to cediranib, this finding suggests that other RTK targets are 
possibly affected by cediranib, in addition to VEGFR, the 
most potent RTK affected, and these other targets may acti-
vate other downstream pathways that affect the invasion and 
migration processes, instead of cell death. Further studies are 
necessary to confirm this hypothesis.
The crosstalk of the EGFR pathways and certain miRNAs 
has been described; for example, EGFR mutations can regu-
late miR-21 in lung cancer and glioblastoma cell lines (73). 
Similarly, miR-145 was found to inhibit cell proliferation by 
targeting EGFR in lung adenocarcinoma and in a model of 
colon cancer (74,75). In the present study, both miRNAs were 
modulated in the hs578T cells, and only miR-21 was down-
regulated in MDA-Mb-231 cells. however, some different 
processes seem to occur in the T47D cells. Considering that 
miR-449 (specific to T47D) can also modulate EGFR, the 
ambiguities of this process should be further explored.
The present study assessed for the first time the anti-
neoplastic effects of cediranib in breast cancer cell lines. 
We observed a distinct degree of response in all the cell 
lines. Cediranib impaired mechanisms leading to cancer 
cell invasion and migration. The present study revealed an 
anti-neoplastic role of cediranib in human breast cancer cell 
lines. Importantly, we identified ROR2 and FGFR2α as novel 
RTK targets of cediranib. The miRNA expression profiling 
revealed the effect of this drug on several miRNAs involved 
in several molecular processes. Finally, more studies are 
necessary to validate these miRNA signatures as indicators 
of the therapeutic response in human breast cancer, and these 
signatures may lead to the selection of patients who would be 
most effectively treated with cediranib.
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